Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel cartilage repair therapy

11.04.2002


Diseases involving irremediable tissue damage of the musculoskeletal system account today for about 15% of hospital admissions in developed countries. With the ageing of the population, this is believed to gain significantly in importance in the coming years.



The majority of the disorders affecting the musculoskeletal system are the joint diseases, in particular osteoarthritis. The latter disease process is typically initiated and associated with defects of the articular cartilage and the underlying bone, causing pain as well as functional impairment. Early tissue repair resulting in the functional restoration of damaged joint surfaces is expected to prevent the development of osteoarthritis, and slow down the progression of the disease.

Different solutions and therapies are currently available for the local treatment of joint surface defects. Ranging from small-scaled arthroscopic debridement with microfracture or osteochondral grafting, to radical surgery involving total joint replacement by implantation of prosthesis. However, as the lifetime of joint prosthesis is limited, and with the ageing of the population, there is an increased need for more long lasting biological repair procedures.


Recent therapeutic approaches aim at repairing the articular cartilage by implantation of expanded cartilage cells. Cells used for the procedure are often autologous chondrocytes (i.e. a patient’s own cartilaginous cells), obtained from the patient`s involved joint via biopsy. Main difficulties with this technology include, amongst others, the so called “de-differentiation” of the cells which, during the in vitro expansion, loose their proper function i.e. the potential to form stable hyaline cartilage. The expanded cells instead can only make disorganized low quality fibro-cartilaginous tissue having different functional properties than the original articular cartilage covering the joints. Many existing therapeutic tissue regeneration methods therefore may lead to failure in mid- and long-term and, sometimes, may even aggravate the local damage.

TiGenix improves the Autologuous Chondrocyte Implantation procedure

The recently founded Belgian company TiGenix has been able to overcome this difficulty, unblocking herewith the way for successful and long-lasting tissue regeneration. Focusing on joint-surface defects and based on its own research, the company has been able to consistently grow the required hyaline-type cartilage in vivo. TiGenix has discovered specific molecular markers which are used to predict the ability of a cell population to form stable hyaline cartilage in vivo.

From these research findings, TiGenix has subsequently developed the cellular therapeutic product ChondroCelect®. ChondroCelect® is a proprietary technology using the patient`s own cells, resulting in a consistent and reproducible cell product, expected to improve the outcome of an autologous chondrocyte implantation procedure.
ChondroCelect® recently entered a prospective randomized clinical trial in 9 orthopedic centers in Belgium. The company actively prepares the extension of the trial to medical centers in other European countries. The commercial launch of ChondroCelect® is foreseen in 2004.

Therapies of next generation

The repair of chondral (cartilage) defects is the first application of TiGenix` research. The company has also identified specific markers that will enable the selection of adult multipotent precursor cells as the basis for next-generation tissue repair. The latter include therapeutic solutions for osteochondral (cartilage and underlying bone) defects and ultimately novel treatment options for osteoarthritis.

Who is TiGenix ?

TiGenix was founded in February 2000 as a spin-off of the University of Leuven (Belgium) by Frank Luyten, M.D., Ph.D., Professor at the Faculty of Medicine of the University of Leuven and Chairman of the Department of Rheumatology at the same university; and Ir. Gil Beyen, Partner at Arthur D. Little in Brussels and specialist in the healthcare sector.

TiGenix is a biomedical company with the mission of developing innovative products for successful repair and functional regeneration of damaged human tissue. The company aims at becoming one of the leading players in the field of musculoskeletal tissue engineering.

To do so, TiGenix is built on a multidisciplinary technology platform, combining expertise in cell and developmental biology, biomaterials and biosurgery. Various collaborations and strategic partnerships have been put in place to ensure the technological advancement and further developments of TiGenix, including with leading research centers, a bioinformatics company as well as Belgian and international experts as scientific advisors.

Currently Tigenix employs 20 people of which 11 are active in Research & Development. The new offices are located near the city of Leuven, while the company`s own GMP cell expansion facilities are located in the premises of the nearby Leuven University hospital center.

To date, TiGenix has been financed through seed capital, in a round led by Gemma Frisius Fund, and through technology grants from the Flemish government. To finance its further development and expansion strategy, the company is currently raising additional equity capital through a private placement.

Patrick Valkenberg | alphagalileo

More articles from Health and Medicine:

nachricht Once invincible superbug squashed by 'superteam' of antibiotics
22.08.2017 | University at Buffalo

nachricht Chronic stress induces fatal organ dysfunctions via a new neural circuit
21.08.2017 | Hokkaido University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Molecular volume control

22.08.2017 | Life Sciences

When fish swim in the holodeck

22.08.2017 | Life Sciences

Biochemical 'fingerprints' reveal diabetes progression

22.08.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>